SpicyIP Weekly Review (February 19- February 25)
Here is our recap of last week’s top IP developments. Last week we published 3 posts on the MHC’s interpretation of Section 3(d) in the Novozymes case, DHC’s referral of 3 questions concerning the jurisdiction of High Courts in trademark rectification matters, and DHC’s decision on infringement of product by process claims. Anything we are missing out on? Let us know by dropping a comment below. Highlights of the Week ‘Non’-Pharmaceutical Substance and Efficacy under Sec 3(d) Can Section 3(d) be […]
SpicyIP Weekly Review (February 19- February 25) Read More »









